High Dose Cladribine in Combination with High Dose
Cytarabine as A Salvage Therapy for Adults with
Refractory Relapsed Langerhans Cell Histiocytosis
Volume 4 - Issue 4
Naif I AlJohani*, Nada AlHarbi, Jalil Ur Rehman, Binyam Usman
- Adult Hematology and Bone marrow transplant section, Oncology Department, King Faisal Specialist Hospital & Research Center, Jeddah,
Saudi Arabia
Received:June 11, 2021 Published: June 22, 2021
Corresponding author: Naif I AlJohani, Section Head & Consultant, Adult Hematology and Bone Marrow Transplant. Oncology
Department, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
DOI: 10.32474/OAJOM.2021.04.000194
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Introduction
Langerhans cell histiocytosis (LCH) is a rare condition with extremely variable manifestations ranging from single-organ
involvement to multisystemic dysfunction that can be refractory or relapse. Currently, no international standard care guidelines
exist for treating adult patients with refractory, multisystem LCH. This case series describes three patients with refractory
multisystem LCH who failed to respond to multiple lines of chemotherapy or radiotherapy but remarkably achieved sustained
complete metabolic remission after treatment with a modified “pediatric-inspired” cladribine-based intensive induction (CLAG)
protocol.
Presentation of Cases
Case 1 was a 29-year-old female who presented with chronic left thigh pain and an abnormal gait. Case 2 was a 39-year-old
male who presented with a 2-year history of generalized body and back pain. Case 3 was a 21-year-old female who presented with
increasing maxillary pain, night sweats, and weight loss. In all three cases, the initial radiological imaging showed osteolytic lesions
and tissue biopsies confirmed the diagnosis of LCH. Case 1 received standard induction chemotherapy and two lines of salvage
therapy before the CLAG protocol was initiated. Case 2 was treated with standard induction chemotherapy, and the CLAG protocol
was used as first line salvage therapy. Case 3 was treated with standard induction chemotherapy and the CLAG protocol used as
second line salvage therapy. In Case 1, maintenance therapy was stopped at 6 months due to recurrent infection and prolonged
cytopenia. In Case 2, significant changes were made to the maintenance phase protocol because of side effects. The CLAG protocol
resulted in complete metabolic remission in all patients based on follow-up PET/CT examinations.
Conclusion
We report 3 cases of refractory/relapsed LCH in adult patients who experienced complete metabolic remission following
salvage chemotherapy using a modified CLAG protocol after failure of at least one line of standard induction therapy.
Keywords: Cladribine; Cytarabine; Langerhans Cell Histiocytosis; Osteolytic Lesions
Abstract|
Introduction|
Clag Protocol|
Case Reports|
Discussion|
Conclusion|
Acknowledgment|
Disclosure|
Ethical Approval and Informed Consent|
Consent for Publication|
Funding|
Authors’ contributions|
References|